One such agent is the third-generation TKI, ponatinib, as initial studies of ponatinib in CML patients indicated that it has clinical activity with remarkable hematologic and cytogenetic responses even in patients with the BCR-ABL-T315I mutation [15], [16]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.